

# Kazimierz Kuliczkowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/866991/publications.pdf>

Version: 2024-02-01

70  
papers

1,190  
citations

471509

17  
h-index

377865

34  
g-index

70  
all docs

70  
docs citations

70  
times ranked

2085  
citing authors

#	ARTICLE	IF	CITATIONS
1	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. <i>Scientific Reports</i> , 2021, 11, 10017.	3.3	3
2	G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells. <i>Cytokine</i> , 2019, 116, 38-47.	3.2	6
3	Efficient method for isolation of reticulocyte RNA from healthy individuals and hemolytic anaemia patients. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 487-496.	3.6	5
4	Comparing radioactive tracers 18F-FDG and 18F-FLT in the staging of diffuse large B-cell lymphoma by PET/CT examination: A single-center prospective study. <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 1095-1099.	1.4	2
5	Influence of temperature rise by 2.5Å°C on the increase of apoptosis of HL-60 cells treated with busulfan. <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 581-585.	1.4	0
6	The analysis of the parameters of 24â€œhr <scp>ECG</scp> Holter monitoring in patients with blood neoplasms undergoing highâ€œdose chemotherapy and stem cell transplantation. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12534.	1.1	6
7	HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor. <i>Human Immunology</i> , 2018, 79, 403-412.	2.4	9
8	Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies. <i>Medical Oncology</i> , 2018, 35, 162.	2.5	1
9	Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia. <i>BMC Cancer</i> , 2018, 18, 107.	2.6	10
10	TThe role of hypoxia-inducible factors in leukemias. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 271-275.	1.4	5
11	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. <i>American Journal of Hematology</i> , 2017, 92, 359-366.	4.1	24
12	Significance of OCT1 Expression in Acute Myeloid Leukemia. <i>Pathology and Oncology Research</i> , 2017, 23, 665-671.	1.9	3
13	Phase 2 study of tabalumab, a human antiâ€œBâ€œcell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , 2017, 176, 783-795.	2.5	39
14	MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2017, 99, 415-422.	2.2	9
15	Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. <i>Leukemia and Lymphoma</i> , 2017, 58, 1598-1606.	1.3	11
16	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1084-1093.	1.3	48
17	A new frameshift mutation of the Î²-spectrin gene associated with hereditary spherocytosis. <i>Annals of Hematology</i> , 2017, 96, 163-165.	1.8	14
18	Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 115-121.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients. <i>Oncotarget</i> , 2016, 7, 30250-30257.	1.8	19
20	The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience. <i>Disease Markers</i> , 2016, 2016, 1-5.	1.3	5
21	The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 147-150.	2.3	10
22	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. <i>Blood</i> , 2016, 128, 630-637.	1.4	69
23	Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia. <i>Oncology Letters</i> , 2016, 12, 2296-2300.	1.8	20
24	Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. <i>Blood</i> , 2016, 127, 360-362.	1.4	34
25	A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. <i>American Journal of Hematology</i> , 2016, 91, 900-906.	4.1	22
26	Echocardiographic evaluation of the early cardiotoxic effect of hematopoietic stem cell transplantation in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2119-2125.	1.3	3
27	Elevated <i>PIM2</i> gene expression is associated with poor survival of patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2140-2149.	1.3	10
28	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq0 0 0 r gBT /Overlock 10 Tf 10.7 135	10.7	135
29	Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation. <i>Cardiovascular Toxicology</i> , 2016, 16, 156-162.	2.7	10
30	Altered Endothelial Cells Properties and Platelets Activity in Treatment Na <sup>+</sup> -Ve Patients with Multiple Myeloma (MM ) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications. <i>Blood</i> , 2016, 128, 5649-5649.	1.4	0
31	Azacitidine in outpatient treatment – single center experience. <i>Wspolczesna Onkologia</i> , 2015, 6, 467-470.	1.4	0
32	The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy. <i>Leukemia Research</i> , 2015, 39, 318-322.	0.8	32
33	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. <i>JAMA Oncology</i> , 2015, 1, 643.	7.1	362
34	Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 68.	8.6	47
35	Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody. <i>Journal of Controlled Release</i> , 2015, 220, 515-528.	9.9	38
36	Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial. <i>Blood</i> , 2015, 126, 5288-5288.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Gemcitabine-Based Treatment in Poor Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 783-789.	1.4	5
38	Hasford Score Is Correlated with 18 Month Molecular Response for Chronic Myeloid Leukemia Patients Treated with Second Generation Tyrosine Kinase Inhibitors and It May be Useful to Differentiate Low and Intermediate Risk Patients: A Single Institution Experience. <i>Blood</i> , 2015, 126, 5163-5163.	1.4	0
39	Decreased Expression of CXCR4 Chemokine Receptor in Bone Marrow after Chemotherapy in Patients with Non-Hodgkin Lymphomas Is a Good Prognostic Factor. <i>PLoS ONE</i> , 2014, 9, e98194.	2.5	20
40	Significance of GRP78 expression in acute myeloid leukemias. <i>Open Medicine (Poland)</i> , 2014, 9, 204-209.	1.3	1
41	Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B. <i>Blood</i> , 2014, 124, 1523-1523.	1.4	1
42	Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results. <i>Blood</i> , 2014, 124, 21-21.	1.4	26
43	High Expression of Mir-15a Predicts Shorter Survival and Worse Response to Chemotherapy in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 5330-5330.	1.4	3
44	Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 531-538.	1.4	3
45	The Occurrence of AL Amyloidosis (Light-Chain Amyloidosis) in Patients with Multiple Myeloma in Lower Silesia Region, Poland. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 235-244.	1.4	2
46	The Hasford Score Correlates with the Long-Term Molecular Response to Imatinib Treatment for Chronic Myeloid Leukemia Patients and May be Useful for Differentiating Low and Intermediate Risk Patients: A Single Institution Experience. <i>Blood</i> , 2014, 124, 3152-3152.	1.4	0
47	A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis. <i>Blood</i> , 2013, 122, 1640-1640.	1.4	1
48	Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA). <i>Blood</i> , 2013, 122, 4061-4061.	1.4	1
49	CD117 (c-kit) Expression On CD34+ Cells Participates In The Cytogenetic Response To Imatinib In CML Patients In First Chronic Phase. <i>Blood</i> , 2013, 122, 3990-3990.	1.4	0
50	Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group. <i>Blood</i> , 2013, 122, 3236-3236.	1.4	0
51	High Expression of Haematopoietic Cell Specific Lyn Substrate-1 (HS1) Predicts Survival of B-Cell Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2011, 118, 2853-2853.	1.4	1
52	Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome. <i>Blood</i> , 2011, 118, 3109-3109.	1.4	0
53	Concentrations of Metalloproteinase-9 (MMP-9), Metalloproteinases -1 and-2 Tissue Inhibitors (TIMP-1), Tj ETQq1 1 0.784314 rgBT / (DKK-1) and Emmprin (CD147) Expression Are Increased in Patients with Myeloma Multiplex and MMP-9 Correlates with advanced Stage of Disease. <i>Blood</i> , 2011, 118, 5069-5069.	1.4	1
54	Expression of PIM-2 and NF- $\kappa$ B Is Increased in Patients with Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) and Correlates with Complete Remission Rate. <i>Blood</i> , 2011, 118, 4648-4648.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Treatment of Elderly Patients with Acute Myeloid Leukemia Adjusted to Age, Performance Status, Organ Function and the Presence of Co-Morbidities. Final Results of the Polish Adult Leukemia Group (PALG) 1/2005 Study.. Blood, 2010, 116, 1067-1067.	1.4	0
56	Coexpression of Bmi-1 and Interleukin-3 Receptor Alpha Chain (CD123) Correlate with Poor Prognosis In Acute Myeloid Leukemia. Blood, 2010, 116, 4324-4324.	1.4	0
57	ICOS Gene Polymorphisms In B-Cell Chronic Lymphocytic Leukemia In a Polish Population.. Blood, 2010, 116, 4614-4614.	1.4	1
58	Gene Expression for Chemokine Receptors Influences Survival of Non-Hodgkin Lymphoma Patients. Blood, 2010, 116, 3103-3103.	1.4	0
59	Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients. Blood, 2008, 112, 133-133.	1.4	3
60	Acquired Inhibitor of Factor VIII Associated with Prostate Cancer: Case Report. Blood, 2008, 112, 4099-4099.	1.4	1
61	The Reduction of Leukemic Blasts In Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia: The Results of Multicenter, Prospective Polish Adult Leukemia Group Study.. Blood, 2008, 112, 1950-1950.	1.4	0
62	CD8+CD28 <sup>+</sup> in Peripheral Blood of Patients with Cutaneous T-Cell Lymphoma (CTLC) in Different Clinical Stages.. Blood, 2007, 110, 4395-4395.	1.4	0
63	Expression of the Human PIM-2 (hPIM-2) Gene in Patients with Acute Myeloblastic Leukaemia (AML) and Acute Lymphoblastic Leukaemia (ALL).. Blood, 2007, 110, 4288-4288.	1.4	0
64	Improved Survival in Acute Myeloid Leukaemia Patients Aged over 40 Given Cladribine in Combination with Standard Remission Induction (DA 3+7) and Consolidation Treatment (HD AraC). Seven Year Follow-Up of Prospective, Cooperative PALG Study.. Blood, 2006, 108, 2003-2003.	1.4	0
65	CCL2 Chemokine Gene Expression in Lymph Nodes May Have Prognostic Value in Non-Hodgkin <sup>TM</sup> s Lymphoma.. Blood, 2006, 108, 4644-4644.	1.4	0
66	CCR5 Chemokine Receptor Expression Can Promote Disease Progression in Non-Hodgkin <sup>TM</sup> s Lymphoma.. Blood, 2006, 108, 4645-4645.	1.4	0
67	sVEGFR3 but Not VEGF-C Plasma Level Is Increased in Non-Hodgkin Lymphoma.. Blood, 2005, 106, 4657-4657.	1.4	0
68	Plasma Gelatinolytic Activity in Leukemias.. Blood, 2004, 104, 3823-3823.	1.4	0
69	Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathology and Oncology Research, 2003, 9, 170-173.	1.9	23
70	p16 INK4a and p15 INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood, 2001, 98, 244-246.	1.4	77